Aimedbio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
0009K0
- Investments
-
5
Aimedbio General Information
Description
Operator of a healthcare company intended to serve patients with serious brain diseases. The company provides therapeutic systems and medicines for neuro-oncological and degenerative diseases, enabling patients with refractory brain disease, including cancer, to have an improved quality of life.
Contact Information
Website
www.aimedbio.comCorporate Office
- 9th Floor, 10th Floor, 11th Floor MK Tower
- 67 Jeongui-ro, Songpa-gu
- Seoul
- South Korea
Corporate Office
- 9th Floor, 10th Floor, 11th Floor MK Tower
- 67 Jeongui-ro, Songpa-gu
- Seoul
- South Korea
Aimedbio Timeline
Aimedbio Financials Summary
As of 31-Dec-2025, Aimedbio has a trailing 12-month revenue of $29.1M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|
| Revenue | 29,077 | 29,077 | 8,648 |
Aimedbio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aimedbio Patents
Aimedbio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026216855-A1 | Anti-ror1 antibody-drug conjugate and use thereof | Pending | 07-Apr-2025 | ||
| WO-2026151284-A1 | Anti-cdcp1 antibody or antigen-binding fragment thereof, antibody-drug conjugate comprising the same, and uses thereof | Pending | 10-Jan-2025 | ||
| WO-2026038910-A1 | Site-specific antibody-drug conjugates comprising benzoselenophene-based compound and use thereof | Pending | 16-Aug-2024 | ||
| WO-2026035116-A1 | Linker-drug conjugate and antibody-drug conjugate both comprising silatecan derivative | Pending | 08-Aug-2024 | ||
| AU-2024414179-A1 | A pharmaceutical composition of anti-fgfr3 antibody drug conjugate and applications thereof | Pending | 27-Dec-2023 | A61P35/00 |
Aimedbio Signals
Aimedbio Investments (5)
Aimedbio’s most recent deal was a Later Stage VC with Regen Innopharm for . The deal was made on 09-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Regen Innopharm | 09-Nov-2026 | Later Stage VC | Biotechnology | ||
| Inocras | 03-Aug-2026 | Later Stage VC | Other Pharmaceuticals and Biotechnology | ||
| AIVIS | 03-Feb-2026 | Later Stage VC | Decision/Risk Analysis | ||
| Regen Innopharm | 01-Mar-2025 | Seed Round | Biotechnology | ||
| SL Therapeutics | 04-Mar-2021 | PIPE | Diagnostic Equipment |
Aimedbio FAQs
-
When was Aimedbio founded?
Aimedbio was founded in 2018.
-
Where is Aimedbio headquartered?
Aimedbio is headquartered in Seoul, South Korea.
-
What is the size of Aimedbio?
Aimedbio has 50 total employees.
-
What industry is Aimedbio in?
Aimedbio’s primary industry is Drug Discovery.
-
Is Aimedbio a private or public company?
Aimedbio is a Public company.
-
What is Aimedbio’s stock symbol?
The ticker symbol for Aimedbio is 0009K0.
-
What is Aimedbio’s current revenue?
The trailing twelve month revenue for Aimedbio is $29.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process